Types of Research
- (-) Remove Literature Review filter Literature Review
- (-) Remove 2017 filter 2017
- (-) Remove Agricultural Inputs & Farm Management filter Agricultural Inputs & Farm Management
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove 2015 filter 2015
- (-) Remove 2019 filter 2019
- (-) Remove Data Analysis filter Data Analysis
- (-) Remove 2008 filter 2008
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Crop yield is one of the most commonly used partial factor productivity measures. It is used to estimate the ratio of quantity of crop output, generally measured in kilograms or tons, to a sole input, land area. Ongoing EPAR research explores the policy implications of measuring yield by area planted versus area harvested. In this brief, we consider implications for crop yield estimates of other decisions in how to construct yield measures from household survey microdata. Using data from three waves of the Tanzania National Panel Survey (TNPS) and two waves of the Ethiopia Socioeconomic Survey (ESS), both part of the World Bank’s Living Standards Measurement Study-Integrated Surveys on Agriculture (LSMS-ISA), we calculate separate crop yield estimates across survey waves following different decisions on disaggregating yield by gender(s) of the plot decision-maker(s) and for pure-stand and mixed stand (intercropped) plots, on including crop production from multiple growing seasons, and on how to treat outlier observations.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.